Summary
Biocartis Group NV (Biocartis) is a molecular diagnostics company that specializes in providing next-generation diagnostic solutions. It carries out Idylla platform, a fully automated, real-time PCR-based system designed for in-house molecular biomarker testing. The company offers oncology test kits including genefusion panel, EGFR mutation test, BRAF mutation test, mutation test, NRAS-BRAF mutation test, MSI test, hepatopredict, colonode, hepatopredict, merlin assay; infectious disease tests, and oncology research assays. Biocartis serves healthcare providers, including pathologists and oncologists, by offering tests for various cancers such as lung, skin, thyroid, colorectal, endometrial, blood, brain and breast cancer. The company operates in the US, and Belgium. Biocartis is headquartered in Mechelen, Flanders, Belgium.This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Biocartis Group NV
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Biocartis Group NV Company Overview
- Biocartis Group NV Company Snapshot
- Biocartis Group NV Pipeline Products and Ongoing Clinical Trials Overview
- Biocartis Group NV - Pipeline Analysis Overview
- Biocartis Group NV - Key Facts
- Biocartis Group NV - Major Products and Services
- Biocartis Group NV Pipeline Products by Development Stage
- Biocartis Group NV Pipeline Products Overview
- APIS Breast Cancer Subtyping Test With Idylla PIK3CA-AKT1 Mutation Assay
- APIS Breast Cancer Subtyping Test With Idylla PIK3CA-AKT1 Mutation Assay Product Overview
- EGFR Colon Cancer Test
- EGFR Colon Cancer Test Product Overview
- Idylla - EGFR/BRAF+ Test
- Idylla - EGFR/BRAF+ Test Product Overview
- Idylla ABC Assay
- Idylla ABC Assay Product Overview
- Idylla Blood Stream Infections Panel
- Idylla Blood Stream Infections Panel Product Overview
- Idylla Brain Cancer Assay
- Idylla Brain Cancer Assay Product Overview
- Idylla Companion Diagnostic Assay
- Idylla Companion Diagnostic Assay Product Overview
- Idylla EGFR CDx Assay
- Idylla EGFR CDx Assay Product Overview
- Idylla Endometrium Assay
- Idylla Endometrium Assay Product Overview
- Idylla Endpoint CDx Test
- Idylla Endpoint CDx Test Product Overview
- Idylla Extended KRAS Mutation Test
- Idylla Extended KRAS Mutation Test Product Overview
- Idylla Extended NRAS Mutation Test
- Idylla Extended NRAS Mutation Test Product Overview
- Idylla Hematology Assay
- Idylla Hematology Assay Product Overview
- Idylla HPV Test - Head And Neck Cancer
- Idylla HPV Test - Head And Neck Cancer Product Overview
- Idylla Immuno Tx Panel Test
- Idylla Immuno Tx Panel Test Product Overview
- Idylla Meningitis Assay
- Idylla Meningitis Assay Product Overview
- Idylla MERS Assay
- Idylla MERS Assay Product Overview
- Idylla Neuro Panel Test
- Idylla Neuro Panel Test Product Overview
- Idylla NGS Prep Panel - Lung
- Idylla NGS Prep Panel - Lung Product Overview
- Idylla Oncotype DX Prostate
- Idylla Oncotype DX Prostate Product Overview
- Idylla Resistance Monitoring Assay
- Idylla Resistance Monitoring Assay Product Overview
- Idylla Retrieve - NGS Hotspot Panel Assay
- Idylla Retrieve - NGS Hotspot Panel Assay Product Overview
- Idylla Sepsis Assay
- Idylla Sepsis Assay Product Overview
- Idylla Syndromic Immunocompromised Panel
- Idylla Syndromic Immunocompromised Panel Product Overview
- Idylla Syndromic Panel - Tropical Fever
- Idylla Syndromic Panel - Tropical Fever Product Overview
- Idylla System - Multiplex Companion Diagnostics Test
- Idylla System - Multiplex Companion Diagnostics Test Product Overview
- Idylla Test - Cell Therapy Monitoring
- Idylla Test - Cell Therapy Monitoring Product Overview
- Idylla Viral Load Assay - HBV
- Idylla Viral Load Assay - HBV Product Overview
- Idylla Viral Load Assay - HCV
- Idylla Viral Load Assay - HCV Product Overview
- Idylla Viral Load Assay - HIV
- Idylla Viral Load Assay - HIV Product Overview
- Rapid Gene Signature Test - Pancreatic Cancer
- Rapid Gene Signature Test - Pancreatic Cancer Product Overview
- SeptiCyte Triage
- SeptiCyte Triage Product Overview
- Biocartis Group NV - Key Competitors
- Biocartis Group NV - Key Employees
- Biocartis Group NV - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Biocartis Group NV, Recent Developments
- Jul 07, 2026: Biocartis NV: Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology Diagnostics
- Mar 10, 2026: Press Release Biocartis NV: Biocartis Receives European IVDR Certification for the Idylla CDx MSI Test
- Nov 14, 2025: Press Release Biocartis NV: Biocartis Showcases Growing Impact of Idylla Platform at AMP 2025
- Sep 15, 2025: Biocartis Receives FDA Approval for Idylla CDx MSI Test
- Sep 15, 2025: Biocartis Receives FDA Approval for the Idylla CDx MSI Test
- Sep 04, 2025: Biocartis Group Received CLIA Approval For Idylla CDx MSI Test
- Aug 28, 2025: Biocartis Group Obtains PMA Approval for Idylla CDx MSI Test
- Jun 02, 2025: Biocartis Announces IVDR Class C CDx Certification of the Idylla EGFR Mutation Test
- Apr 02, 2025: Biocartis Announces Launch of the Brand-New Idylla POLE-POLD1 Mutation Assay
- Mar 18, 2025: Biocartis Announces Multiple Abstracts Demonstrating the Impact of Idylla in Oncology Diagnostics To Be Presented at USCAP 2025 Annual Meeting
- Appendix
- Methodology
- About the Analyst
- Contact Us
- Disclaimer
- Biocartis Group NV Pipeline Products and Ongoing Clinical Trials Overview
- Biocartis Group NV Pipeline Products by Equipment Type
- Biocartis Group NV Pipeline Products by Indication
- Biocartis Group NV, Key Facts
- Biocartis Group NV, Major Products and Services
- Biocartis Group NV Number of Pipeline Products by Development Stage
- Biocartis Group NV Pipeline Products Summary by Development Stage
- APIS Breast Cancer Subtyping Test With Idylla PIK3CA-AKT1 Mutation Assay - Product Status
- APIS Breast Cancer Subtyping Test With Idylla PIK3CA-AKT1 Mutation Assay - Product Description
- EGFR Colon Cancer Test - Product Status
- EGFR Colon Cancer Test - Product Description
- Idylla - EGFR/BRAF+ Test - Product Status
- Idylla - EGFR/BRAF+ Test - Product Description
- Idylla ABC Assay - Product Status
- Idylla ABC Assay - Product Description
- Idylla Blood Stream Infections Panel - Product Status
- Idylla Blood Stream Infections Panel - Product Description
- Idylla Brain Cancer Assay - Product Status
- Idylla Brain Cancer Assay - Product Description
- Idylla Companion Diagnostic Assay - Product Status
- Idylla Companion Diagnostic Assay - Product Description
- Idylla EGFR CDx Assay - Product Status
- Idylla EGFR CDx Assay - Product Description
- Idylla Endometrium Assay - Product Status
- Idylla Endometrium Assay - Product Description
- Idylla Endpoint CDx Test - Product Status
- Idylla Endpoint CDx Test - Product Description
- Idylla Extended KRAS Mutation Test - Product Status
- Idylla Extended KRAS Mutation Test - Product Description
- Idylla Extended NRAS Mutation Test - Product Status
- Idylla Extended NRAS Mutation Test - Product Description
- Idylla Hematology Assay - Product Status
- Idylla Hematology Assay - Product Description
- Idylla HPV Test - Head And Neck Cancer - Product Status
- Idylla HPV Test - Head And Neck Cancer - Product Description
- Idylla Immuno Tx Panel Test - Product Status
- Idylla Immuno Tx Panel Test - Product Description
- Idylla Meningitis Assay - Product Status
- Idylla Meningitis Assay - Product Description
- Idylla MERS Assay - Product Status
- Idylla MERS Assay - Product Description
- Idylla Neuro Panel Test - Product Status
- Idylla Neuro Panel Test - Product Description
- Idylla NGS Prep Panel - Lung - Product Status
- Idylla NGS Prep Panel - Lung - Product Description
- Idylla Oncotype DX Prostate - Product Status
- Idylla Oncotype DX Prostate - Product Description
- Idylla Resistance Monitoring Assay - Product Status
- Idylla Resistance Monitoring Assay - Product Description
- Idylla Retrieve - NGS Hotspot Panel Assay - Product Status
- Idylla Retrieve - NGS Hotspot Panel Assay - Product Description
- Idylla Sepsis Assay - Product Status
- Idylla Sepsis Assay - Product Description
- Idylla Syndromic Immunocompromised Panel - Product Status
- Idylla Syndromic Immunocompromised Panel - Product Description
- Idylla Syndromic Panel - Tropical Fever - Product Status
- Idylla Syndromic Panel - Tropical Fever - Product Description
- Idylla System - Multiplex Companion Diagnostics Test - Product Status
- Idylla System - Multiplex Companion Diagnostics Test - Product Description
- Idylla Test - Cell Therapy Monitoring - Product Status
- Idylla Test - Cell Therapy Monitoring - Product Description
- Idylla Viral Load Assay - HBV - Product Status
- Idylla Viral Load Assay - HBV - Product Description
- Idylla Viral Load Assay - HCV - Product Status
- Idylla Viral Load Assay - HCV - Product Description
- Idylla Viral Load Assay - HIV - Product Status
- Idylla Viral Load Assay - HIV - Product Description
- Rapid Gene Signature Test - Pancreatic Cancer - Product Status
- Rapid Gene Signature Test - Pancreatic Cancer - Product Description
- SeptiCyte Triage - Product Status
- SeptiCyte Triage - Product Description
- Biocartis Group NV, Key Employees
- Biocartis Group NV, Subsidiaries
- Glossary
- Biocartis Group NV Pipeline Products by Equipment Type
- Biocartis Group NV Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Nyxoah SA
- Ion Beam Applications SA
- FEops nv
